BioCentury
ARTICLE | Clinical News

Lomitapide: Additional Phase III data

November 23, 2009 8:00 AM UTC

Additional data from an ongoing, open-label Phase III trial in 14 evaluable patients treated for at least 26 weeks showed that lomitapide titrated up to 60 mg/day reduced mean LDL-C by 49%. Average ba...